We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 07, 2015

Glipizide vs Dapagliflozin as an Adjunct to Metformin Therapy

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Long-Term Glycaemic Response and Tolerability of Dapagliflozin Versus a Sulphonylurea as Add-On Therapy to Metformin in Patients With Type 2 Diabetes: 4-Year Data
Diabetes Obes Metab 2015 Jun 01;17(6)581-590, S Del Prato, M Nauck, S Durán-Garcia, L Maffei, K Rohwedder, A Theuerkauf, S Parikh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading